For the Inventor, By the Inventor

Enter assignee name

Sanofi-Aventis

Calculating rank

USPTO Granted Patents = 390

% Expired Patents = 75.9

CIPO Patents = 9

EPO Patents = 90

Trademarks = 27

Forward Citations = 1,591

Loading Chart...

Loading Chart...

633 inventors (with patents filed for the assignee):

Alistair Lochead (39 out of 75 patents)

Francis Barth (29 out of 41 patents)

Mourad Saady (27 out of 44 patents)

4. Philippe Yaiche (26 out of 43 patents)

5. Murielle Rinaldi-Carmona (25 out of 32 patents)

6. Pierre Casellas (24 out of 48 patents)

7. Christian Congy (22 out of 31 patents)

8. Christian Hoornaert (19 out of 26 patents)

9. Bernard Bourrie (19 out of 30 patents)

10. Yannick Evanno (18 out of 40 patents)

11. Samir Jegham (17 out of 39 patents)

12. Stefanie Keil (16 out of 42 patents)

13. Franck Slowinski (16 out of 19 patents)

14. Ahmed Abouabdellah (16 out of 23 patents)

15. Karl Schoenafinger (15 out of 55 patents)

Core Competencies:

Multiple Myeloma

Pharmaceuticals

Safety Assembly

Syringe

Pyrazole Derivatives

Nuclear Receptor

Thromboembolic Disorders

CB1 Receptor

Dihydroisoquinolines

Antithrombotic Activity

HSP90 Inhibitors

Factor Xa Inhibitors

390 patents: Sort by Forward Citations

1. 12655222 - Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Uses (2026-06-16),

2. 11939390 - Methods of treating multiple myeloma (2024-03-26),

3. 9090411 - Apparatus and method for loading and unloading containers (2015-07-28),

4. 8979794 - Safety assembly for a syringe (2015-03-17),

5. 8946212 - Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals (2015-02-03),

6. 8933097 - Fexofenadine suspension formulation (2015-01-13),

7. 8800759 - Bushing for receiving a dropper neck, and corresponding package and kit (2014-08-12),

8. 8684652 - Apparatus and method for loading and unloading containers (2014-04-01),

9. 8680096 - Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators (2014-03-25),

10. 8633321 - Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof (2014-01-21),

11. 8617105 - Safety assembly for a syringe (2013-12-31),

12. 8614219 - Substituted pyrimidin-4-one derivatives (2013-12-24),

13. 8461175 - 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof (2013-06-11),

14. 8410286 - Substituted pyrazoles, compositions containing these, method of production and use (2013-04-02),

15. 8308696 - Needle sheathing device with flexible end-piece for syringe (2012-11-13),

Company Overview

Sanofi-Aventis, headquartered in Paris, France, is a global leader in the pharmaceutical industry, focusing on the development and manufacturing of innovative therapies. The company specializes in areas such as multiple myeloma, thromboembolic disorders, and safety assembly technologies, including advanced syringe systems. With a strong emphasis on pharmaceutical chemistry, Sanofi-Aventis is dedicated to addressing complex health challenges through research on various core technologies, including pyrazole derivatives and nuclear receptors.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

390 Patents

#24 in Paris

#65 in France

#2,365 in the World

Sanofi-Aventis

Forward Citations = 1,591

633 inventors:

Alistair Lochead (39 out of 75 patents)

Francis Barth (29 out of 41 patents)

Mourad Saady (27 out of 44 patents)

4. Philippe Yaiche (26 out of 43 patents)

5. Murielle Rinaldi-Carmona (25 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sanofi-Aventis. Retrieved from https://idiyas.com/company/sanofi-aventis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…